BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank0
3Y CAGR-37.5%
5Y CAGR-49.5%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-37.5%/yr
vs -31.1%/yr prior
5Y CAGR
-49.5%/yr
Recent acceleration
Acceleration
-6.5pp
Decelerating
Percentile
P0
Near historical low
vs 5Y Ago
0x
Contraction
Streak
5 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 2.31 | -54.5% |
| 2024 | 5.08 | -9.7% |
| 2023 | 5.63 | -40.7% |
| 2022 | 9.49 | -41.9% |
| 2021 | 16.35 | -76.8% |
| 2020 | 70.37 | +830.6% |
| 2019 | 7.56 | -82.0% |
| 2018 | 42.02 | +152.5% |
| 2017 | 16.64 | -12.0% |
| 2016 | 18.90 | - |